Israel Englander Tenaya Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 680,744 shares of TNYA stock, worth $517,365. This represents 0.0% of its overall portfolio holdings.

Number of Shares

680,744

Previous 42,050 1518.89%

Holding current value

$517,365

Previous $23,000 1704.35%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.39 - $0.69 $249,090 - $440,698	638,694 Added 1518.89%	680,744 $415,000
Q1 2025 May 15, 2025	SELL	$0.44 - $1.52 $49,358 - $170,510	-112,178 Reduced 72.74%	42,050 $23,000
Q4 2024 Feb 14, 2025	SELL	$1.23 - $3.78 $214,569 - $659,409	-174,447 Reduced 53.08%	154,228 $220,000
Q3 2024 Nov 14, 2024	BUY	$1.93 - $3.99 $92,667 - $191,575	48,014 Added 17.11%	328,675 $634,000
Q2 2024 Aug 14, 2024	SELL	$2.72 - $4.99 $256,879 - $471,260	-94,441 Reduced 25.18%	280,661 $870,000
Q1 2024 May 15, 2024	SELL	$2.88 - $6.8 $367,395 - $867,462	-127,568 Reduced 25.38%	375,102 $1.96 Million
Q4 2023 Feb 14, 2024	BUY	$1.73 - $3.39 $285,209 - $558,878	164,861 Added 48.8%	502,670 $1.63 Million
Q2 2023 Aug 14, 2023	BUY	$2.64 - $7.64 $467,810 - $1.35 Million	177,201 Added 110.33%	337,809 $1.98 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $3.59 $92,956 - $173,809	48,415 Added 43.15%	160,608 $458,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $3.19 $25,482 - $48,385	15,168 Added 15.63%	112,193 $226,000
Q3 2022 Nov 14, 2022	BUY	$2.9 - $5.88 $247,654 - $502,140	85,398 Added 734.48%	97,025 $281,000

Others Institutions Holding TNYA

# of Institutions

Shares Held

37M

Call Options Held

91.4K

Put Options Held

50.3K

View Full List

About Tenaya Therapeutics, Inc.

Ticker TNYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,364,700
Market Cap $31.4M
Description
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...

More about TNYA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account